PDF / 34 KB 
collectBayerNews_20090902_0501_en.pdf BayerNews_20090902_0501_en.pdf
Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate® and NeoBenz® Micro
Berlin, Germany, September 2, 2009 - Intendis GmbH, which is part of Bayer
HealthCare, announced today that it has signed an agreement to acquire two
prescription dermatology product lines from SkinMedica, Inc., a dermatology
company based in Carlsbad, CA, USA.
Both Desonate® and NeoBenz® Micro are currently marketed in the U.S. by
SkinMedica, Inc. Under the transaction, which is still subject to the necessary
regulatory approvals, Intendis will acquire all commercial rights, including
assigned contracts and intellectual property related to the two product lines.
The deal is expected to close in the Fall of 2009.
"We are currently seeing solid growth of our existing portfolio of prescription
dermatologicals in the U.S. With the addition of these two high-quality product
lines we expect to build on this dynamic and to substantially strengthen our
presence in this key strategic business," stated Marc Lafeuille, President and
CEO of the Intendis Group. In 2008, the company grew by 18.7% on a
currency-adjusted basis in the U.S.
Desonate® is a low potency topical corticosteroid for the treatment of mild to
moderate atopic dermatitis, an inflammatory skin disease. Formulated in a
waterbased Hydrogel vehicle, it is indicated for patients as young as 3 months.
NeoBenz® Micro is a benzoyl peroxide medication for the treatment of mild to
moderate acne vulgaris. Its special formulation allows for a gradual release of
the active ingredient which allows for an effective treatment with only low
irritation.
"We are pleased that this agreement with Intendis will allow us to devote
investments to continued growth of our remaining dermatology business," said
Mary Fisher, President and CEO of SkinMedica. "We look forward to expanding our
pipeline of innovative products for the improvement of skin appearance and the
treatment of dermatologic conditions."
About Intendis
Intendis is an integrated pharmaceutical company based in Berlin, Germany. As
part of Bayer HealthCare, Intendis is completely dedicated to Dermatology and
focuses on the development, manufacturing and marketing of high quality,
innovative topical therapies, targeted to treat skin disorders. The current
product portfolio comprises treatments of eczema disorders including atopic
dermatitis, as well as psoriasis, acne, rosacea, hemorrhoids and fungal skin
infections (mycoses). Find out more at www.intendis.com.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Bayer Schering
Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com.
About SkinMedica
SkinMedica, Inc. is focused on developing, acquiring and commercializing
products that treat dermatologic conditions and improve the appearance of skin.
SkinMedica markets and sells, primarily to dermatologists, both prescription
pharmaceutical products and physician-dispensed, non-prescription skin care
products. SkinMedica is based in Carlsbad, California. For more information,
visit: www.skinmedica.com.
Desonate®, EpiQuin® Micro, NeoBenz® Micro, SkinMedica®, TNS Recovery Complex®
and VANIQA® are registered trademarks of SkinMedica, Inc and affiliates.
You are leaving the Bayer AG website.
Bayer AG is not responsible for the information on the website to which you are linking.
